Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

  1. Sousa, B.B.
  2. de Almeida, C.R.
  3. Barahona, A.F.
  4. Lopes, R.
  5. Martins-Logrado, A.
  6. Cavaco, M.
  7. Neves, V.
  8. Carvalho, L.A.R.
  9. Labaõ-Almeida, C.
  10. Coelho, A.R.
  11. Bento, M.L.
  12. Lopes, R.M.R.M.
  13. Oliveira, B.L.
  14. Castanho, M.A.R.B.
  15. Neumeister, P.
  16. Deutsch, A.
  17. Vladimer, G.I.
  18. Krall, N.
  19. Joaõ, C.
  20. Corzana, F.
  21. Seixas, J.D.
  22. Fior, R.
  23. Bernardes, G.J.L.
Revista:
ACS Pharmacology and Translational Science

ISSN: 2575-9108

Any de publicació: 2022

Volum: 5

Número: 11

Pàgines: 1156-1168

Tipus: Article

DOI: 10.1021/ACSPTSCI.2C00163 GOOGLE SCHOLAR lock_openAccés obert editor
Repositori institucional: lock_openAccés obert Editor